XML 75 R62.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting - Reconciliation of Revenue to Net Profit (Loss) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2025
Sep. 30, 2024
Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]                
Total revenue $ 100,055     $ 82,883     $ 271,419 $ 247,206
Less:                
Depreciation and amortization expense             11,136 10,833
Stock-based compensation expense 8,418     16,923     26,773 49,895
Litigation settlement expense 0     0     5,710 0
Interest income, net (2,013)     (3,001)     (7,161) (8,712)
Net income (loss) 1,675 $ (8,568) $ (10,353) (10,637) $ (4,623) $ (19,888) (17,246) (35,148)
Testing services revenue                
Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]                
Total revenue 72,168     60,807     196,122 185,562
Less:                
Cost of test services, product, and patient and digital solutions 14,705     13,447     45,224 41,387
Product revenue                
Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]                
Total revenue 12,478     10,212     35,121 29,416
Less:                
Cost of test services, product, and patient and digital solutions 5,629     6,212     16,196 17,854
Patient and digital solutions revenue                
Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]                
Total revenue 15,409     11,864     40,176 32,228
Less:                
Cost of test services, product, and patient and digital solutions 10,320     7,913     26,307 22,264
Reportable Segment                
Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]                
Total revenue 100,055     82,883     271,419 247,206
Less:                
Personnel cost 33,915     29,186     93,988 86,557
Professional and legal fees 10,307     10,224     32,847 32,430
Research materials and clinical trials expense 1,791     3,526     9,022 11,730
Depreciation and amortization expense 3,020     3,040     8,921 9,526
Stock-based compensation expense 8,418     16,923     26,773 49,895
Litigation settlement expense 0     0     5,710 0
Transformational initiative costs 524     0     2,395 0
Other segment items 13,179     7,946     33,149 25,396
Interest income, net (2,013)     (3,001)     (7,160) (8,713)
Net income (loss) 1,675     (10,637)     (17,246) (35,148)
Reportable Segment | Testing services revenue                
Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]                
Total revenue 72,168     60,807     196,122 185,562
Less:                
Cost of test services, product, and patient and digital solutions 14,058     12,700     43,192 39,168
Reportable Segment | Product revenue                
Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]                
Total revenue 12,478     10,212     35,121 29,416
Less:                
Cost of test services, product, and patient and digital solutions 5,131     5,559     14,505 15,828
Reportable Segment | Patient and digital solutions revenue                
Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items]                
Total revenue 15,409     11,864     40,176 32,228
Less:                
Cost of test services, product, and patient and digital solutions $ 10,050     $ 7,417     $ 25,323 $ 20,537